GHP Investment Advisors’s Charles River Laboratories CRL Stock Holding History

GHP Investment Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.9K	Hold	26	–	–	﹤0.01%	869
2026 Q1	$4.49K	Hold	26	–	–	﹤0.01%	916
2025 Q4	$5.19K	Hold	26	–	–	﹤0.01%	813
2025 Q3	$4.07K	Hold	26	–	–	﹤0.01%	810
2025 Q2	$3.94K	Sell	26 -16	-38%	-$2.13K	﹤0.01%	819
2025 Q1	$6.32K	Buy	+42	New	+$7.04K	﹤0.01%	744
2023 Q4	–	Sell	-63	Closed	-$12K	–	866
2023 Q3	$12K	Buy	+63	New	+$12.9K	﹤0.01%	671
2023 Q1	–	Sell	-37	Closed	-$8.06K	–	927
2022 Q4	$8.06K	Buy	+37	New	+$8.08K	﹤0.01%	724

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

GHP Investment Advisors's CRL Position: Q2 2026 in Review

GHP Investment Advisors held its Charles River Laboratories (CRL) position steady in Q2 2026 at 26 shares worth $5.9K. The position accounts for ﹤0.01% of the portfolio, ranked #869.

GHP Investment Advisors first reported a position in CRL in Q4 2022 and has held it in 8 quarters since. The position peaked at $12K in Q3 2023. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

GHP Investment Advisors held 26 shares of Charles River Laboratories worth $5.9K as of Q2 2026.
GHP Investment Advisors left its Charles River Laboratories share count unchanged in Q2 2026.
Charles River Laboratories made up ﹤0.01% of GHP Investment Advisors's portfolio in Q2 2026, its #869 holding.
GHP Investment Advisors first reported a position in Charles River Laboratories in Q4 2022 and has held it in 8 quarters since.
GHP Investment Advisors's Charles River Laboratories position peaked at $12K in Q3 2023.
563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on GHP Investment Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.